NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)
Psychiatric Times
JUNE 23, 2025
1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. 1 The company has previously filed the required Chemistry, Manufacturing, and Controls (CMC) information and received FDA feedback.
58 
Let's personalize your content